PMID- 19837091
OWN - NLM
STAT- MEDLINE
DCOM- 20100303
LR  - 20091204
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 28
IP  - 2
DP  - 2009 Dec 11
TI  - Comparison of monocyte-derived dendritic cells from colorectal cancer patients, 
      non-small-cell-lung-cancer patients and healthy donors.
PG  - 542-7
LID - 10.1016/j.vaccine.2009.09.129 [doi]
AB  - Dendritic cells (DCs) are bone marrow-derived professional antigen presenting 
      cells. Due to their role as potent inducers of immune responses, these cells are 
      widely used as adjuvant in experimental clinical settings for cancer immune 
      therapy. We have developed a DC-based vaccine using autologous blood monocytes 
      loaded with allogeneic tumor cell lysate rich in cancer/testis antigens. This 
      vaccine has at present been tested for activity in three phase II clinical trials 
      including two cohorts of patients with advanced colorectal cancer (CRC) and one 
      cohort of patients with advanced non-small-cell-lung-cancer (NSCLC). In the 
      present paper we retrospectively compare the maturation profile based on surface 
      marker expression on DCs generated from the three patient cohorts and between 
      cancer patient cohorts and a cohort of healthy donors. Vaccines were generated 
      under cGMP conditions and phenotypic profiles of DC were analyzed by flow 
      cytometry and the obtained data were used as a basis to set guideline values for 
      our quality control of GMP produced DC vaccines. Each vaccine batch was analyzed 
      for the expression of the surface maturation and differentiation molecules CD14, 
      CD1a, CD83, CD86, MHC class II and CCR7, and the optimal expression pattern is 
      considered as CD14(low), CD1a, CD83(high), CD86(high), MHC class II(high) and 
      CCR7(high). In accordance with data from other studies including other types of 
      cancer patients, especially breast cancer patients, we found that the maturation 
      status of the DC batches depends on cancer type and correlates with clinical 
      status of cancer patients included.
FAU - Kvistborg, P
AU  - Kvistborg P
AD  - DanDrit Biotech A/S, Symbion Science Park, Copenhagen, Denmark.
FAU - Bechmann, C M
AU  - Bechmann CM
FAU - Pedersen, A W
AU  - Pedersen AW
FAU - Toh, H C
AU  - Toh HC
FAU - Claesson, M H
AU  - Claesson MH
FAU - Zocca, M B
AU  - Zocca MB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091104
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/*immunology
MH  - Carcinoma, Non-Small-Cell Lung/*immunology
MH  - Colorectal Neoplasms/*immunology
MH  - Dendritic Cells/*cytology/*immunology
MH  - Flow Cytometry
MH  - Humans
MH  - Monocytes/*cytology
EDAT- 2009/10/20 06:00
MHDA- 2010/03/04 06:00
CRDT- 2009/10/20 06:00
PHST- 2009/06/30 00:00 [received]
PHST- 2009/09/08 00:00 [revised]
PHST- 2009/09/29 00:00 [accepted]
PHST- 2009/10/20 06:00 [entrez]
PHST- 2009/10/20 06:00 [pubmed]
PHST- 2010/03/04 06:00 [medline]
AID - S0264-410X(09)01489-3 [pii]
AID - 10.1016/j.vaccine.2009.09.129 [doi]
PST - ppublish
SO  - Vaccine. 2009 Dec 11;28(2):542-7. doi: 10.1016/j.vaccine.2009.09.129. Epub 2009 
      Nov 4.